Unknown

Dataset Information

0

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.


ABSTRACT: BACKGROUND AND OBJECTIVES:Biomarkers may improve identification of individuals at risk of eGFR decline who may benefit from intervention or dialysis planning. However, available biomarkers remain incompletely validated for risk stratification and prediction modeling. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:We examined serum cystatin C, urinary kidney injury molecule-1 (uKIM-1), and urinary neutrophil gelatinase-associated lipocalin (UNGAL) in 5367 individuals with type 2 diabetes mellitus and recent acute coronary syndromes enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial. Baseline concentrations and 6-month changes in biomarkers were also evaluated. Cox proportional regression was used to assess associations with a 50% decrease in eGFR, stage 5 CKD (eGFR<15 ml/min per 1.73 m2), or dialysis. RESULTS:eGFR decline occurred in 98 patients (1.8%) over a median of 1.5 years. All biomarkers individually were associated with higher risk of eGFR decline (P<0.001). However, when adjusting for baseline eGFR, proteinuria, and clinical factors, only baseline cystatin C (adjusted hazard ratio per 1 SD change, 1.66; 95% confidence interval, 1.41 to 1.96; P<0.001) and 6-month change in urinary neutrophil gelatinase-associated lipocalin (adjusted hazard ratio per 1 SD change, 1.07; 95% confidence interval, 1.02 to 1.12; P=0.004) independently associated with CKD progression. A base model for predicting kidney function decline with nine standard risk factors had strong discriminative ability (C-statistic 0.93). The addition of baseline cystatin C improved discrimination (C-statistic 0.94), but it failed to reclassify risk categories of individuals with and without eGFR decline. CONCLUSIONS:The addition of cystatin C or biomarkers of tubular injury did not meaningfully improve the prediction of eGFR decline beyond common clinical factors and routine laboratory data in a large cohort of patients with type 2 diabetes and recent acute coronary syndrome. PODCAST:This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_01_16_CJASNPodcast_18_3_G.mp3.

SUBMITTER: Garlo KG 

PROVIDER: S-EPMC5967667 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo Katherine G KG   White William B WB   Bakris George L GL   Zannad Faiez F   Wilson Craig A CA   Kupfer Stuart S   Vaduganathan Muthiah M   Morrow David A DA   Cannon Christopher P CP   Charytan David M DM  

Clinical journal of the American Society of Nephrology : CJASN 20180116 3


<h4>Background and objectives</h4>Biomarkers may improve identification of individuals at risk of eGFR decline who may benefit from intervention or dialysis planning. However, available biomarkers remain incompletely validated for risk stratification and prediction modeling.<h4>Design, setting, participants, & measurements</h4>We examined serum cystatin C, urinary kidney injury molecule-1 (uKIM-1), and urinary neutrophil gelatinase-associated lipocalin (UNGAL) in 5367 individuals with type 2 dia  ...[more]

Similar Datasets

| S-EPMC7606554 | biostudies-literature
| S-EPMC6923196 | biostudies-literature
| S-EPMC8564071 | biostudies-literature
| S-EPMC7509983 | biostudies-literature
| S-EPMC6105325 | biostudies-literature
2023-03-11 | PXD027870 | Pride
| S-EPMC9729784 | biostudies-literature
| S-EPMC4848189 | biostudies-literature
| S-EPMC10291814 | biostudies-literature
| S-EPMC10577370 | biostudies-literature